The First Affiliated Hospital of Xiamen University
192
74
87
30
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.5%
1 terminated/withdrawn out of 192 trials
96.8%
+10.3% vs industry average
13%
24 trials in Phase 3/4
0%
0 of 30 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (192)
Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients
Role: collaborator
Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease
Role: lead
Beta-Blockers on Neoadjuvant Immunochemotherapy for Hypertensive Patients With Gastric Cancer
Role: collaborator
rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)
Role: collaborator
ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer
Role: lead
Flexible Ureteroscopy With a Flexible and Navigable Suction Ureteral Access Sheath Versus Mini-Percutaneous Nephrolithotomy for 1-2 cm Lower Pole Kidney Stones
Role: collaborator
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
Role: lead
The Combined Multicomponent Intervention Specifically in Rural Community Older Adults at High Risk for Mild Cognition Impairment
Role: collaborator
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
Role: collaborator
Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition
Role: collaborator
A Phase II Study of NB001 for Acute Migraine Treatment
Role: collaborator
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
Role: collaborator
Multi-Site Cortical Puncture for DOR
Role: collaborator
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Role: lead
Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
Role: collaborator
PRL3-Zumab in Patients With Advanced Solid Tumors
Role: collaborator
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
Role: lead
Time Restricted Eating on Impaired Glucose Regulation(TRIG Trial)
Role: lead
Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer
Role: lead
Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome
Role: collaborator